The Biosimilars Forum Applauds Launch of New FDA Performance Dashboard
Following the release of the FDA’s new Biosimilar User Fee Act (BsUFA) Performance Dashboard, the Biosimilars Forum released the following statement:
We applaud the FDA for launching its new Biosimilar User Fee Act (BsUFA) performance dashboard that provides transparent information on the development and performance of biosimilars. This is an important step by the FDA as it continues its commitment to expedite the biosimilars’ review process and works to bring these life-saving treatments to the market.
Patients are demanding access to lower-cost drugs and biosimilars are providing the solution. Biosimilars are FDA-approved treatments that are just as effective as their reference biologic and can save patients and taxpayers billions of dollars over the next decade. We believe this public dashboard will help doctors and patients see for themselves how these lower-cost alternatives continue to meet the FDA’s rigorous standards of approval and, therefore, must be immediately accessible to patients. We look forward to the BsUFA continuing to strengthen the program and allow for patients to access lower-cost treatments.